NewSquare Capital’s ADMA Biologics ADMA Stock Holding History

NewSquare Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200	Closed	-$738	–	600
2023 Q2	$738	Hold	200	–	–	﹤0.01%	642
2023 Q1	$662	Hold	200	–	–	﹤0.01%	690
2022 Q4	$776	Buy	+200	New	+$617	﹤0.01%	610

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

NewSquare Capital's ADMA Position: Q3 2023 in Review

NewSquare Capital sold out of ADMA Biologics (ADMA) in Q3 2023, closing a stake of 200 shares — an estimated $738 sold.

NewSquare Capital first reported a position in ADMA in Q4 2022 and held it in 3 quarters. The position peaked at $776 in Q4 2022. 188 funds tracked by Wall St. Rank hold ADMA as of Q3 2023.

NewSquare Capital reported no remaining ADMA Biologics position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 200 ADMA Biologics shares in Q3 2023, an estimated $738.
NewSquare Capital first reported a position in ADMA Biologics in Q4 2022 and held it in 3 quarters.
NewSquare Capital's ADMA Biologics position peaked at $776 in Q4 2022.
188 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.